Aprocitentan, sold under the brand name Tryvio, is approved for patients with high blood pressure who are already taking other antihypertensive drugs. 

More than 5,000 U.S. physicians joined forces to launch the new group. They say they are focused on limiting private equity's involvement and influence in healthcare. 

These findings may say a lot more about a patient's long-term health than clinicians realized. 

Biotronik's Freesolve technology, which gained CE mark approval in February, is designed to maximize blood flow and minimize the post-implantation risks of stent thrombosis and target lesion revascularization.

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

The Heart Failure Society of America shared a new scientific statement about this topic, noting that many patients may require additional help.

This is a Class I recall, which means using the device “may cause serious injuries or death.” However, the FDA emphasized that this is a correction and not a product removal.

President Joe Biden signed a funding bill worth $460 billion on March 9, but it only included partial relief for cardiologists, cardiac surgeons and other cardiology professionals.